Senior health ministry officials said on Thursday that it will take around one-and-a-half to two years for India to develop a vaccine for novel coronavirus even with expedited clinical trials.
The novel coronavirus has affected 73 people in the country, including 17 foreign nationals.
The 17 affected foreign nationals include 16 Italians and a Canadian patient.
Raman R Gangakhedkar, head of the Epidemiology and Communicable Diseases-I (ECD-I), Division of ICMR said the National Institute of Virology in Pune has been successful in isolating the virus.
"There are two ways of going for vaccine preparation. One is either you look at the sequences of the gene which then may lead to development of antibodies, or you actually have the strain and then you try to develop a vaccine which is always an easier option," he said.
"Coronavirus is difficult to isolate. But the efforts of scientists of National Institute of Virology (NIV) Pune have been successful and about 11 isolates of coronavirus are available which is a prime requisite for doing any kind of research related to viruses. Even with expedited clinical trials and approvals, it will take around one-and-a-half to two years to develop a vaccine," Gangakhedkar asserted.
The official said the Indian government has made 52 laboratories functional for testing samples, while 57 labs have been designated for helping in sample collection for
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
